Global ETD Search

Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.

Results

Showing 1 to 20 of 723 for “"Multiple Myeloma"”.

  1. Immunotherapy in multiple myeloma

    The BDCA antibodies allowed reliable measurement of dendritic cell (DC) subsets and B cell numbers in the blood of normal subjects, and patients with MM throughout the disease course. The numbers of blood myeloid DC (BmDC) and blood plasmacytoid DC (BpDC) are low throughout the course of the …

    glasgow Download PDF for Immunotherapy in multiple myeloma (opens in a new tab)

  2. Targeting Autophagy in Multiple Myeloma

    Apoptosis (Type I) and autophagy (Type II) represent two major forms of programmed cell death. Numerous anticancer agents employed in standard chemotherapy or novel targeted therapy induce both apoptosis and autophagy. Of note, a cytoprotective autophagic response often counteracts apoptosis …

    vcu Repository record for Targeting Autophagy in Multiple Myeloma (opens in a new tab)

  3. Risk Factors Associated With Multiple Myeloma

    Multiple myeloma (MM) is a hematologic malignancy in which clonal plasma cells accumulate in the bone marrow, leading to the formation of lytic bone lesions, hypercalcemia, anemia, renal insufficiency, and immunosuppression. It develops from a pre-malignant condition known as monoclonal gammopathy …

    uab Repository record for Risk Factors Associated With Multiple Myeloma (opens in a new tab)

  4. The Role of SAMSN1 in Multiple Myeloma

    Multiple myeloma (MM) is a haematological malignancy characterised by the uncontrolled clonal proliferation of neoplastic plasma cells (PCs) within the bone marrow (BM). Our group previously identified a homozygous deletion of Samsn1, a gene encoding a putative adaptor protein, in the genome of the …

    adelaide Repository record for The Role of SAMSN1 in Multiple Myeloma (opens in a new tab)

  5. The TAM receptor family in multiple myeloma

    Multiple myeloma (MM) is a haematological malignancy of antibody secreting monoclonal plasma cells (PCs) in the bone marrow (BM). MM PC growth and survival is supported by other cells within the BM microenvironment including osteoblasts, osteoclasts, bone marrow stromal cells and immune cells. …

    adelaide Repository record for The TAM receptor family in multiple myeloma (opens in a new tab)

  6. The role of TWIST1 in multiple myeloma

    Multiple myeloma (MM) is an incurable haematological malignancy characterised by the uncontrolled proliferation of clonal plasma cells (PCs) in the bone marrow (BM). MM disease progression relies on the continuous trafficking of MM PCs to distant BM sites leading to multiple focal tumours …

    adelaide Repository record for The role of TWIST1 in multiple myeloma (opens in a new tab)

  7. The Role of Gremlin1 in Multiple Myeloma

    Multiple myeloma (MM) is a fatal haematological malignancy characterised by the clonal proliferation of malignant plasma cells (PC) within the bone marrow (BM). In most instances, MM PCs are reliant on factors made by cells of the BM stroma for their survival and growth. To date, the nature and …

    adelaide Repository record for The Role of Gremlin1 in Multiple Myeloma (opens in a new tab)

  8. Preclinical Imaging of Multiple Myeloma Therapy Response

    Multiple myeloma (MM) is a debilitating hematologic malignancy of terminally differentiated plasma cells in the bone marrow (BM). Advances in therapeutic regimens and the use of autologous stem cell transplantation have significantly improved survival rates and quality of life in patients. However, …

    wustl Repository record for Preclinical Imaging of Multiple Myeloma Therapy Response (opens in a new tab)

  9. Disruption of chromosome territories in Multiple Myeloma

    Background: Multiple Myeloma (MM) is an oligoclonal cancer of plasma cells. Currently, MM is an incurable disease. MM displays altered gene expression, chromosome aberrations and altered chromosome position, which contributes to high genomic instability of MM cells. Lamin A/C is a nuclear protein …

    manitoba Repository record for Disruption of chromosome territories in Multiple Myeloma (opens in a new tab)

  10. Cell-Free Dna Sequencing In Multiple Myeloma

    <p>Multiple myeloma (MM) is an incurable plasma cell dyscrasia. Recent advances in MM therapy, including CAR-T therapy, have increased survival and shown the value of assessing treatment response with great sensitivity, both in acute and long-term settings. Cell-free DNA, DNA fragments which are …

    uthsc Repository record for Cell-Free Dna Sequencing In Multiple Myeloma (opens in a new tab)

  11. An Investigation of 53BP1 in Multiple Myeloma

    Currently, multiple myeloma is the second most common hematological malignancy, and as of yet it remains incurable. Although many therapeutic advances have been made in the recent past, there is still room for improvement in the treatment of myeloma. Here, using CRISPR/Cas9 genome editing, we show …

    calgary Repository record for An Investigation of 53BP1 in Multiple Myeloma (opens in a new tab)

  12. Investigating T Cell Exhaustion in Multiple Myeloma

    Multiple Myeloma (MM) is a currently incurable malignancy of plasma cells. Immunotherapies are widely agreed upon to be the most likely avenue through which a cure could be found, however, to become longer lasting, permanent solutions, immunotherapies must overcome persistent antigenic stimulation …

    calgary Repository record for Investigating T Cell Exhaustion in Multiple Myeloma (opens in a new tab)

  13. Approaches to targeted therapy in multiple myeloma

    Multiple Myeloma (MM) is the second most common hematological malignancy, and although patient outcomes have significantly improved since the introduction of autologous stem cell transplantation (ASCT) and novel pharmacological agents such as immunomodulators (IMID), proteasome inhibitors (PI), and …

    bu Repository record for Approaches to targeted therapy in multiple myeloma (opens in a new tab)

  14. Targeting sphingolipid metabolism proteasome inhibitor-resistant multiple myeloma

    Multiple myeloma (MM) is a cancer arising from plasma cells, the cells which produce antibodies. Whilst the introduction of therapies such as proteasome inhibitors (PIs) has greatly extended life expectancy, MM is still an incurable disease as resistance regularly develops. I have developed a new …

    adelaide Repository record for Targeting sphingolipid metabolism proteasome inhibitor-resistant multiple myeloma (opens in a new tab)

  15. Genetic changes in the development of multiple myeloma

    Multiple myeloma (MM) is a malignancy of clonal plasma cells (PC) which develops as a consequence of a multistep process of transformation from a normal PC to an asymptomatic stage known as monoclonal gammopathy of undetermined significance (MGUS) to MM to the more aggressive plasma cell leukaemia …

    soton Download PDF for Genetic changes in the development of multiple myeloma (opens in a new tab)

  16. ROLE OF JAGGED IN MULTIPLE-MYELOMA-ASSOCIATED ANGIOGENESIS

    Il mieloma multiplo è una neoplasia delle plasma cellule ancora incubabile, caratterizzata dall’accumulo di cellule tumorali nel midollo osseo. Durante la progressione dalla fase di Gammopatia monoclonale a significato incerto (MGUS) a mieloma multiplo diverse modifiche avvengono sia nelle plasma …

    milano Repository record for ROLE OF JAGGED IN MULTIPLE-MYELOMA-ASSOCIATED ANGIOGENESIS (opens in a new tab)

  17. PRECLINICAL TESTING OF GALECTIN-3C FOR MULTIPLE MYELOMA

    … that there will be more than 20,000 new cases of multiple myeloma (MM) in the US in 2011 and despite the new treatments now available, the median survival rate is only 5 years. Galectin-3C (Gal-3C) is a human lectin involved in cellular processes including cellular differentiation, apoptosis, …

    milano Repository record for PRECLINICAL TESTING OF GALECTIN-3C FOR MULTIPLE MYELOMA (opens in a new tab)

Page 1 of 37